Oxford BioMedica ( (GB:OXB) ) just unveiled an update.
Oxford Biomedica PLC announced the appointment of Colin Bond, a Non-Executive Director, to a similar role at Faron Pharmaceuticals Ltd, an AIM-listed company. This move reflects OXB’s strategic positioning within the cell and gene therapy industry, potentially strengthening its network and influence through leadership roles in related companies.
More about Oxford BioMedica
OXB (LSE: OXB) is a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapy. The company focuses on viral vector development and manufacturing, collaborating with pharmaceutical and biotechnology companies to deliver life-changing therapies. OXB’s capabilities include a range of viral vector types and unique technologies for manufacturing, supported by quality assurance and regulatory expertise. Headquartered in Oxford, UK, OXB operates facilities in the UK, France, and the US.
YTD Price Performance: -26.14%
Average Trading Volume: 6,263
Technical Sentiment Signal: Buy
Current Market Cap: $421.8M
Find detailed analytics on OXB stock on TipRanks’ Stock Analysis page.